全文获取类型
收费全文 | 3881690篇 |
免费 | 324433篇 |
国内免费 | 23433篇 |
专业分类
耳鼻咽喉 | 51628篇 |
儿科学 | 121024篇 |
妇产科学 | 98843篇 |
基础医学 | 601302篇 |
口腔科学 | 104254篇 |
临床医学 | 357217篇 |
内科学 | 685910篇 |
皮肤病学 | 99833篇 |
神经病学 | 320438篇 |
特种医学 | 150752篇 |
外国民族医学 | 306篇 |
外科学 | 589282篇 |
综合类 | 141833篇 |
现状与发展 | 63篇 |
一般理论 | 2364篇 |
预防医学 | 319674篇 |
眼科学 | 92202篇 |
药学 | 275241篇 |
257篇 | |
中国医学 | 21941篇 |
肿瘤学 | 195192篇 |
出版年
2021年 | 61677篇 |
2020年 | 40422篇 |
2019年 | 62118篇 |
2018年 | 76334篇 |
2017年 | 59371篇 |
2016年 | 64458篇 |
2015年 | 80575篇 |
2014年 | 116162篇 |
2013年 | 181808篇 |
2012年 | 115884篇 |
2011年 | 118029篇 |
2010年 | 129735篇 |
2009年 | 131132篇 |
2008年 | 101119篇 |
2007年 | 105139篇 |
2006年 | 113707篇 |
2005年 | 107708篇 |
2004年 | 107030篇 |
2003年 | 96679篇 |
2002年 | 85382篇 |
2001年 | 138052篇 |
2000年 | 131378篇 |
1999年 | 123219篇 |
1998年 | 69296篇 |
1997年 | 65996篇 |
1996年 | 63578篇 |
1995年 | 59039篇 |
1994年 | 52982篇 |
1993年 | 49180篇 |
1992年 | 85273篇 |
1991年 | 81184篇 |
1990年 | 76880篇 |
1989年 | 75255篇 |
1988年 | 69174篇 |
1987年 | 67330篇 |
1986年 | 63607篇 |
1985年 | 62818篇 |
1984年 | 54904篇 |
1983年 | 49605篇 |
1982年 | 43633篇 |
1981年 | 41005篇 |
1980年 | 38464篇 |
1979年 | 44844篇 |
1978年 | 38236篇 |
1977年 | 34918篇 |
1976年 | 31965篇 |
1975年 | 30785篇 |
1974年 | 32479篇 |
1973年 | 31181篇 |
1972年 | 29036篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
891.
目的本研究以护理结局分类(NOC)为基础,筛选符合慢性心力衰竭患者的相关护理结局,由此构建具有专科专病特点的慢性心力衰竭患者护理结局评价表。方法成立研究核心小组,应用文献回顾法、专家函询法确定护理结局分类指标,并进行统计学分析,最终建立慢性心力衰竭护理结局分类评价表。结果通过研究,确定慢性心力衰竭护理结局中包含4个领域、8个一级指标、68个二级指标。4个领域分别是生理健康、功能健康、健康知识和行为、心理社会健康。一级指标中包含心脏泵血功能、活动耐力、社会支持、抑郁水平等。二级指标中包含心脏指数、血压、呼吸困难、情绪波动大、步行距离、步行速度等68个指标。统计学分析中:第一、二轮函询专家的积极系数分别为90%、100%,专家权威系数为0.895,专家意见协调程度(P<0.05)。结论本研究成功建立慢性心力衰竭护理结局分类评价表,有助于临床护士用于评价护理措施的有效性,也使其成为一种标准化语言,便于应用到护理电子信息系统中进行绩效测算等。但是本研究不足之处是未能将该研究进行临床实证,未能进一步确认其有效性。 相似文献
892.
Fast,sensitive and specific diagnosis of infections with Leishmania spp. in formalin‐fixed,paraffin‐embedded skin biopsies by cytochrome b polymerase chain reaction
下载免费PDF全文
![点击此处可从《The British journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. Gebhardt B. Ertas T.M. Falk N. Blödorn‐Schlicht D. Metze A. Böer‐Auer 《The British journal of dermatology》2015,173(5):1239-1249
893.
Toidi Adekambi Chris C. Ibegbu Stephanie Cagle Ameeta S. Kalokhe Yun F. Wang Yijuan Hu Cheryl L. Day Susan M. Ray Jyothi Rengarajan 《The Journal of clinical investigation》2015,125(5):1827-1838
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center. 相似文献
894.
Jenny U. Johansson Nathaniel S. Woodling Qian Wang Maharshi Panchal Xibin Liang Angel Trueba-Saiz Holden D. Brown Siddhita D. Mhatre Taylor Loui Katrin I. Andreasson 《The Journal of clinical investigation》2015,125(1):350-364
Microglia, the innate immune cells of the CNS, perform critical inflammatory and noninflammatory functions that maintain normal neural function. For example, microglia clear misfolded proteins, elaborate trophic factors, and regulate and terminate toxic inflammation. In Alzheimer’s disease (AD), however, beneficial microglial functions become impaired, accelerating synaptic and neuronal loss. Better understanding of the molecular mechanisms that contribute to microglial dysfunction is an important objective for identifying potential strategies to delay progression to AD. The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated in preclinical AD development, both in human epidemiology studies and in transgenic rodent models of AD. Here, we evaluated murine models that recapitulate microglial responses to Aβ peptides and determined that microglia-specific deletion of the gene encoding the PGE2 receptor EP2 restores microglial chemotaxis and Aβ clearance, suppresses toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and prevents synaptic injury and memory deficits. Our findings indicate that EP2 signaling suppresses beneficial microglia functions that falter during AD development and suggest that inhibition of the COX/PGE2/EP2 immune pathway has potential as a strategy to restore healthy microglial function and prevent progression to AD. 相似文献
895.
896.
Thomas W. McDade Alexander V. Georgiev Christopher W. Kuzawa 《Evolution, Medicine, and Public Health》2016,2016(1):1-16
Immune defenses provide resistance against infectious disease that is critical to survival. But immune defenses are costly, and limited resources allocated to immunity are not available for other physiological or developmental processes. We propose a framework for explaining variation in patterns of investment in two important subsystems of anti-pathogen defense: innate (non-specific) and acquired (specific) immunity. The developmental costs of acquired immunity are high, but the costs of maintenance and activation are relatively low. Innate immunity imposes lower upfront developmental costs, but higher operating costs. Innate defenses are mobilized quickly and are effective against novel pathogens. Acquired responses are less effective against novel exposures, but more effective against secondary exposures due to immunological memory. Based on their distinct profiles of costs and effectiveness, we propose that the balance of investment in innate versus acquired immunity is variable, and that this balance is optimized in response to local ecological conditions early in development. Nutritional abundance, high pathogen exposure and low signals of extrinsic mortality risk during sensitive periods of immune development should all favor relatively higher levels of investment in acquired immunity. Undernutrition, low pathogen exposure, and high mortality risk should favor innate immune defenses. The hypothesis provides a framework for organizing prior empirical research on the impact of developmental environments on innate and acquired immunity, and suggests promising directions for future research in human ecological immunology. 相似文献
897.
898.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
899.
900.